Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Chen, Zonglin ^a   Gerhold Ay, Aslihan ^a   Gebhard, Susanne ^a   Boehm, Daniel ^a   Solbach, Christine ^a   Lebrecht, Antje ^a   Battista, Marco ^a   Sicking, Isabel ^a   Cotarelo, Christina ^a   Cadenas, Cristina ^b   Marchan, Rosemarie ^b   Stewart, Joanna D ^b   Gehrmann, Mathias ^c   Koelbl, Heinz ^a   Hengstler, Jan G ^b   Schmidt, Marcus ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

^c BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMMUNOGLOBULIN KAPPA C; IMMUNOGLOBULIN KAPPA CHAIN; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PLASMA CELL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED;

EID: 84867009247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044741     Document Type: Article

References (28)

1. Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9 (6): 606-616. Available: doi:10.1634/theoncologist.9-6-606.
2. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (27): 2817-2826. Available: doi:10.1056/NEJMoa041588.
3. van Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (6871): 530-536. Available: doi:10.1038/415530a.
4. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, et al. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17 (18): 6012-6020. Available: doi:10.1158/1078-0432.CCR-11-0926.
5. DeNardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9 (4): 212. Available: doi:10.1186/bcr1746.
6. Pagès F, Galon J, Dieu-Nosjean M, Tartour E, Sautès-Fridman C, et al. (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29 (8): 1093-1102. Available: doi:10.1038/onc.2009.416.
7. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, et al. (2011) Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58 (7): 1107-1116. Available: doi:10.1111/j.1365-2559.2011.03846.x.
8. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, et al. (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29 (15): 1949-1955. Available: doi:10.1200/JCO.2010.30.5037.
9. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, et al. (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 11 (2): R15. Available: doi:10.1186/bcr2234.
10. Schmidt M, Böhm D, Törne C von, Steiner E, Puhl A, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68 (13): 5405-5413. Available: doi:10.1158/0008-5472.CAN-07-5206.
11. Mahmoud SMA, Lee AHS, Paish EC, Macmillan RD, Ellis IO, et al. (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res. Treat. 132 (2): 545-553. Available: doi:10.1007/s10549-011-1620-1.
12. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, et al. (2012) A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 18 (9): 2695-2703. Available: doi:10.1158/1078-0432.CCR-11-2210.
13. Li Q, Lao X, Pan Q, Ning N, Yet J, et al. (2011) Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 17 (15): 4987-4995. Available: doi:10.1158/1078-0432.CCR-11-0207.
14. Wang Y, Ylera F, Boston M, Kang S, Kutok JL, et al. (2007) Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Breast Cancer Res. Treat. 104 (2): 129-144. Available: doi:10.1007/s10549-006-9409-3.
15. Rosenblatt J, Zhang YD, Tadmor T (2007) Inhibition of antitumor immunity by B cells. Cancer Res. 67 (10): 5058-9; author reply 5059. Available: doi:10.1158/0008-5472.CAN-06-3903.
16. Tadmor T, Zhang Y, Cho H, Podack ER, Rosenblatt JD (2011) The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol. Immunother. 60 (5): 609-619. Available: doi:10.1007/s00262-011-0972-z.
17. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, et al. (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4? T cells to T-regulatory cells. Cancer Res. 71 (10): 3505-3515. Available: doi:10.1158/0008-5472.CAN-10-4316.
18. Kim S, Fridlender ZG, Dunn R, Kehry MR, Kapoor V, et al. (2008) B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J. Immunother. 31 (5): 446-457. Available: doi:10.1097/CJI.0b013e31816d1d6a.
19. Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, et al. (2009) Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann. Oncol. 20 (2): 258-264. Available: doi:10.1093/annonc/mdn590.
20. Weikel W, Beck T, Mitze M, Knapstein PG, (1991) Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res. Treat. 18 (3): 149-154.
21. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, et al. (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22 (8): 1736-1747. Available: doi:10.1093/annonc/mdr304.
22. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 100 (2): 229-235. Available: doi:10.1007/s10549-006-9242-8.
23. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, et al. (2007) High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 67 (22): 10669-10676. Available: doi:10.1158/0008-5472.CAN-07-0539.
24. Lee AHS, Gillett CE, Ryder K, Fentiman IS, Miles DW, et al. (2006) Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology 48 (6): 692-701. Available: doi:10.1111/j.1365-2559.2006.02410.x.
25. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, et al. (2010) Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and-negative cancers. J. Clin. Oncol. 28 (28): 4316-4323. Available: doi:10.1200/JCO.2009.27.2419.
26. Srlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98 (19): 10869-10874. Available: doi:10.1073/pnas.191367098.
27. Calabrò A, Beissbarth T, Kuner R, Stojanov M, Benner A, et al. (2009) Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res. Treat. 116 (1): 69-77. Available: doi:10.1007/s10549-008-0105-3.
28. Oh E, Choi Y, Park T, Lee S, Nam SJ, et al. (2012) A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity. Breast Cancer Res. Treat. 132 (2): 499-509. Available: doi:10.1007/s10549-011-1626-8.